ReviewFrontiers in surgery2026
The value of robot-assisted gastrectomy in the treatment of gastric cancer: a systematic review and meta-analysis.
Review in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Open gastrectomy (OG) has long been the standard for gastric cancer surgery. Robotic gastrectomy (RG) has emerged as a minimally invasive alternative with potential technical advantages, but large-sample meta-analyses comparing their clinical value are limited. This study aims to evaluate its clinical practical application value and provide a reference for clinical practice. Methods: A systematic search was conducted in PubMed, EMBASE, MEDLINE, Web of Science, and Cochrane Library up to July 2025, following PRISMA guidelines, with statistical analysis using STATA 12. Results: Seventeen studies involving 31,573 patients (10,524 RG, 21,049 OG) were included. RG had longer operative time (WMD: 93.4; 95% CI: 65.89-120.9; Conclusion: RG is a reasonable choice for proficient robotic surgery centers, balancing invasiveness and oncological precision. Future studies should focus on long-term outcome and quality of life to guide clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.